Chromatographic modalities, buffer selection and other considerations for enrichment of AAV product
Sponsor
Adeno-associated virus (AAV) is a go-to vector for gene therapy treatments. In each AAV downstream process, one of the key steps (and often a bottleneck) is enrichment of full capsids. Along with scalability and capsid separation challenges, one must account for sample heterogeneity and assess which analytics are adequate to distinguish between AAV subpopulations and deliver only the potent AAV product.
Chromatography on monolith columns offers efficient and scalable downstream processes. Paramount considerations for scaling up will be discussed and a case study will be presented using a Design of Experiments approach for buffer selection and robust preparation for improved separation of empty and full capsids. In addition, residual host cell proteins, host cell DNA, plasmid DNA, and endotoxin removal efficiency will be discussed.
- Chromatographic columns and their differences for AAV empty/full separation
- Why orthogonal analytics are paramount for AAV subspecies characterization
- Case study of a Design of Experiments approach to enrichment of full capsids
- Considerations for scaling up AAV purification on monoliths
SPEAKERS
You might also like
From process development to manufacturing: how to successfully optimize and scale up the AAV enrichment step on novel CIMmultus QA HR line
Scalable chromatographic strategies for mRNA and saRNA purification from IVT
Considerations in leveraging the Universal AAV Standard for dPCR to assess AAV genomes quantity and quality
Process in the product: a new analytical tool for AAV production optimization and monitoring
